Viewing a single comment thread. View all comments

watabadidea t1_j5xsl0i wrote

Reply to comment by shiruken in The bivalent mRNA boosters from Pfizer-BioNTech and Moderna were 48% effective against symptomatic infection from the predominant omicron subvariant (XBB/XBB.1.5) in persons aged 18-49 years according to early data published by the CDC by shiruken

So what were the actual incident rates for the different groups? That seems like pretty valuable information for any cost/benefit analysis, right?

2